Skip to main content

int230-6

Generic: cisplatin; vinblastine sulfate; SHAO·Code: INT230-6

int230-6: sourced relationships with 1 company · 1 clinical trial tracked.

int230-6 evidence translation

What we can confirm

What it means

Source-backed records connect int230-6 to INTS; that link alone does not prove the drug works.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

How could int230-6 → INTS affect its developer, and what evidence supports the link?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence1 indications · 0 study sponsors

Related indications

Sarcoma,Soft Tissue

Study sponsors

No additional listed-company sponsor is linked.

Dated Pipeline Records (1)
CompanyDated record stage
INTENSITY THERAPEUTICS, INC. (INTS)
owner · Reported 2026-03-27 · Current development: unknownSource
Sarcoma,Soft Tissue
Phase 3
Clinical Trial Registry Records (1)

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adults With Locally Recurrent, InoperaBLE, or Metastatic Soft Tissue Sarcomas (INVINCIBLE-3)

NCT06263231Registry updated 2026-08-11·Phase 3·INTS
Recruiting

Primary endpoint: Overall Survival (OS)

InterventionalRandomizedopen333 targetStarted 2024-06Completion 2028-1217 sites · Canada, France, Germany, Spain…Intensity Therapeutics, Inc.

Frequently asked questions

Which companies have sourced relationships with int230-6?

int230-6 has dated SEC/FDA relationship records for INTENSITY THERAPEUTICS, INC..

How many clinical trials involve int230-6?

BioSniper tracks 1 clinical trial involving int230-6.